ZA200204078B - Production of vaccines. - Google Patents

Production of vaccines.

Info

Publication number
ZA200204078B
ZA200204078B ZA200204078A ZA200204078A ZA200204078B ZA 200204078 B ZA200204078 B ZA 200204078B ZA 200204078 A ZA200204078 A ZA 200204078A ZA 200204078 A ZA200204078 A ZA 200204078A ZA 200204078 B ZA200204078 B ZA 200204078B
Authority
ZA
South Africa
Prior art keywords
virus
production
vaccines
viruses
human cells
Prior art date
Application number
ZA200204078A
Other languages
English (en)
Inventor
Maria Grazia Pau
Govert Johan Schouten
Alphonsus Gerardus C Uytdehaag
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240914&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200204078(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of ZA200204078B publication Critical patent/ZA200204078B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36211—Rubivirus, e.g. rubella virus
    • C12N2770/36251—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ZA200204078A 1999-11-26 2002-05-22 Production of vaccines. ZA200204078B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99203983A EP1103610A1 (en) 1999-11-26 1999-11-26 Production of vaccines from immortalised mammalian cell lines

Publications (1)

Publication Number Publication Date
ZA200204078B true ZA200204078B (en) 2003-08-22

Family

ID=8240914

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200204078A ZA200204078B (en) 1999-11-26 2002-05-22 Production of vaccines.

Country Status (21)

Country Link
EP (3) EP1103610A1 (xx)
JP (1) JP4331432B2 (xx)
KR (2) KR20060107868A (xx)
CN (1) CN1306033C (xx)
AT (1) ATE286537T1 (xx)
AU (2) AU775966B2 (xx)
BR (1) BR0015846A (xx)
CA (1) CA2392653C (xx)
DE (1) DE60017234T3 (xx)
DK (1) DK1108787T4 (xx)
EA (1) EA006136B1 (xx)
ES (1) ES2235770T5 (xx)
HK (1) HK1057236A1 (xx)
IL (2) IL149788A0 (xx)
MX (1) MXPA02005237A (xx)
NO (1) NO333527B1 (xx)
NZ (1) NZ527942A (xx)
PT (1) PT1108787E (xx)
SI (1) SI1108787T2 (xx)
WO (1) WO2001038362A2 (xx)
ZA (1) ZA200204078B (xx)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000326A1 (en) 1995-06-15 1997-01-03 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
WO2004042042A1 (en) * 2002-11-08 2004-05-21 Crucell Holland B.V. Vaccines against west nile virus
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
KR100964413B1 (ko) 2001-01-19 2010-06-15 비로노바티브 비.브이. 감응성 포유류에서 호흡계 질환을 유발하는 바이러스
EP1256803A1 (en) 2001-05-07 2002-11-13 Crucell Holland B.V. Methods for the identification of antiviral compounds
AU2002225509A1 (en) * 2001-12-07 2003-06-17 Crucell Holland B.V. Production and of viruses, viral isolates and vaccines
NZ533124A (en) 2001-12-07 2005-11-25 Crucell Holland B Production of viruses, viral isolates and vaccines
DK1456238T3 (da) 2001-12-17 2008-08-18 Crucell Holland Bv Produktion af F(ab')2-fragmenter i pattedyrceller
JP4553589B2 (ja) 2002-02-21 2010-09-29 メディミューン，エルエルシー 組換えパラインフルエンザウイルス発現系とメタニューモウイルスから得られる異種抗原を含むワクチン
AU2003271738C1 (en) 2002-04-25 2008-04-17 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
EP1590450A2 (en) * 2002-12-20 2005-11-02 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
CN1813061B (zh) * 2003-04-25 2013-05-29 免疫医疗有限责任公司 重组副流感病毒表达系统以及包含源自间质肺病毒的异种抗原的疫苗
AU2004236440B2 (en) * 2003-05-09 2008-10-09 Crucell Holland B.V. Cultures of E1-immortalized cells and processes for culturing the same to increase product yields therefrom
DK1670925T3 (da) 2003-10-02 2013-07-08 Crucell Holland Bv Pakningsceller til rekombinat adenovirus
CA2555412C (en) 2004-02-23 2013-06-25 Crucell Holland B.V. Virus purification methods
WO2005095578A1 (en) * 2004-03-05 2005-10-13 Dsm Ip Assets B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
EP1722815A1 (en) 2004-03-09 2006-11-22 Chiron Corporation Influenza virus vaccines
ES2647491T3 (es) 2004-05-21 2017-12-21 Novartis Vaccines And Diagnostics, Inc. Vectores del alfavirus para las vacunas del virus de la gripe
PT1789084E (pt) * 2004-09-09 2011-02-22 Novartis Vaccines & Diagnostic Redução de riscos iatrogénicos pontenciais associados às vacinas contra a gripe
JP2006090864A (ja) * 2004-09-24 2006-04-06 Denka Seiken Co Ltd ワクチン中の特定成分の含量を求める方法
KR101316350B1 (ko) 2004-12-08 2013-10-15 메디뮨 엘엘씨 인플루엔자 백신 조성물의 제조 방법
WO2006067122A2 (en) 2004-12-20 2006-06-29 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US8574595B2 (en) 2005-04-11 2013-11-05 Crucell Holland B.V. Virus purification using ultrafiltration
AU2006245734C1 (en) 2005-05-12 2012-05-24 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
CN101228267B (zh) * 2005-07-22 2013-01-23 克鲁塞尔荷兰公司 生产冠状病毒的细胞系
PL1951296T5 (pl) 2005-11-01 2015-06-30 Seqirus Uk Ltd Szczepionki wirusowe otrzymane z komórek o niskim poziomie pozostałości DNA komórkowego poprzez traktowanie beta-propiolaktonem
JP5092129B2 (ja) 2006-07-14 2012-12-05 ディーエスエム アイピー アセッツ ビー．ブイ． 細胞を培養する改善された方法
AU2008270317B2 (en) * 2007-07-03 2013-12-05 Transgene S.A. Immortalized avian cell lines
CA2705716C (en) * 2007-12-13 2013-03-19 F. Hoffmann-La Roche Ag Novel rubella e1 envelope protein variants and their use in the detection of anti-rubella antibodies
CN101998990B (zh) * 2008-03-18 2013-11-27 诺华股份有限公司 流感病毒疫苗抗原制备方法的改进
WO2009152181A1 (en) * 2008-06-11 2009-12-17 Flugen, Inc. Cell-based systems for producing influenza vaccines
AU2009272857B2 (en) * 2008-07-15 2015-06-18 Crucell Holland B.V. Scalable process for culturing PER.C6 cells and producing products therefrom
EP2168987A1 (en) * 2008-09-22 2010-03-31 Mucosis B.V. Multifunctional linker protein containing an antibody against hemagglutinin, a conserved influenza antigen and an immunostimulating carrier binding domain
WO2010046335A1 (en) * 2008-10-21 2010-04-29 Crucell Holland B.V. Production of influenza virus by reverse genetics in per.c6 cells under serum free conditions
JP2012507272A (ja) 2008-11-05 2012-03-29 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規な方法
SI2454364T1 (sl) 2009-07-16 2014-08-29 Crucell Holland B.V. Izdelava polio virusa v visokih titrih za izdelavo cepiva
EP2563909A1 (en) 2010-04-26 2013-03-06 Novartis AG Improved production of virus replicon particles in packaging cells
EP4098324A1 (en) 2010-10-11 2022-12-07 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
AU2012211278B2 (en) 2011-01-26 2016-11-10 Glaxosmithkline Biologicals Sa RSV immunization regimen
US20140271829A1 (en) 2011-10-11 2014-09-18 Anders Lilja Recombinant self-replicating polycistronic rna molecules
US20140348863A1 (en) 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
CN102526720B (zh) * 2012-01-11 2013-12-11 中国人民解放军军事医学科学院微生物流行病研究所 一种流感病毒疫苗的制备方法
CA2866465A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Improved vaccination against influenza
CN102631673A (zh) * 2012-04-17 2012-08-15 金宇保灵生物药品有限公司 口蹄疫疫苗浓缩纯化方法
AU2014228275B2 (en) 2013-03-15 2019-03-14 Genzyme Corporation High-density cell banking methods
CN117958251A (zh) 2014-09-18 2024-05-03 建新公司 超高密度细胞建库方法
AR102548A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
RU2745567C2 (ru) 2014-12-17 2021-03-29 Фундасион Пара Ла Инвестигасион Медика Апликада Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний
EP3744351A1 (en) 2014-12-17 2020-12-02 Fundacion para la Investigacion Medica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson's disease and other conditions
EP3764098B1 (en) * 2015-07-07 2022-11-16 Seqirus UK Limited Influenza potency assays
ES2642723B1 (es) 2016-05-12 2018-10-22 Servizo Galego De Saúde (Sergas) Uso de los niveles de anticuerpos anti-CD26 como biomarcadores de enfermedades autoinmunes y/o inflamatorias.
AU2018359556B2 (en) 2017-11-03 2021-12-02 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
SG11202004926WA (en) 2017-12-01 2020-06-29 Encoded Therapeutics Inc Engineered dna binding proteins
KR20200015323A (ko) 2018-08-03 2020-02-12 에릭스바이오(주) 바이러스 치료 장치 또는 백신 제조 장치
SG11202103681UA (en) 2018-10-12 2021-05-28 Vivet Therapeutics Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3)
EP4257155A3 (en) 2018-11-16 2024-02-28 Encoded Therapeutics, Inc. Compositions and methods for treating wilson's disease
EP3965811A1 (en) 2019-05-08 2022-03-16 Takeda Vaccines, Inc. Inactivated virus compositions and zika vaccine formulations
EP4192961A2 (en) 2020-08-06 2023-06-14 Fundacion para la Investigacion Medica Aplicada Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy
US20230265456A1 (en) 2020-08-10 2023-08-24 Fundacion Para La Investigacion Medica Aplicada Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
CA3195052A1 (en) 2020-10-09 2022-04-14 UCB Biopharma SRL Nucleic acid constructs, viral vectors and viral particles
CN118434876A (zh) 2021-10-28 2024-08-02 Ucb生物制药有限责任公司 核酸构建体、病毒载体和病毒颗粒
WO2023154043A1 (en) 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
WO2024059507A1 (en) 2022-09-12 2024-03-21 Akero Therapeutics, Inc. Fgf21 mutant polypeptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3547779A (en) * 1968-12-18 1970-12-15 Merck & Co Inc Process for producing purified concentrated influenza virus
US5192539A (en) * 1988-07-21 1993-03-09 Akzo N.V. Infectious bursal disease virus production in continuous cell lines
FR2723740B1 (fr) * 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
US5989805A (en) * 1995-10-27 1999-11-23 Board Of Trustees Operating Michigan State University Immortal avian cell line to grow avian and animal viruses to produce vaccines

Also Published As

Publication number Publication date
DK1108787T4 (da) 2009-04-14
HK1057236A1 (en) 2004-03-19
BR0015846A (pt) 2002-07-16
EA200200604A1 (ru) 2002-12-26
KR20020064910A (ko) 2002-08-10
CA2392653A1 (en) 2001-05-31
CN1433472A (zh) 2003-07-30
CN1306033C (zh) 2007-03-21
NO20022500L (no) 2002-07-26
ES2235770T5 (es) 2009-05-01
BRPI0015846B8 (xx) 2021-05-25
AU775966B2 (en) 2004-08-19
EP1108787B1 (en) 2005-01-05
PT1108787E (pt) 2005-04-29
CA2392653C (en) 2011-03-29
AU2557201A (en) 2001-06-04
WO2001038362A2 (en) 2001-05-31
IL149788A (en) 2010-12-30
NO333527B1 (no) 2013-07-01
EP1103610A1 (en) 2001-05-30
EP1108787B2 (en) 2008-12-10
WO2001038362A3 (en) 2002-02-14
JP2003516733A (ja) 2003-05-20
MXPA02005237A (es) 2003-09-22
EP1514937A1 (en) 2005-03-16
ATE286537T1 (de) 2005-01-15
EA006136B1 (ru) 2005-10-27
NZ527942A (en) 2004-07-30
SI1108787T1 (en) 2005-06-30
DE60017234D1 (de) 2005-02-10
NO20022500D0 (no) 2002-05-27
EP1108787A2 (en) 2001-06-20
SI1108787T2 (sl) 2009-06-30
KR20060107868A (ko) 2006-10-16
AU2004203642A1 (en) 2004-09-02
IL149788A0 (en) 2002-11-10
DE60017234T3 (de) 2009-07-09
DE60017234T2 (de) 2005-12-08
JP4331432B2 (ja) 2009-09-16
BRPI0015846B1 (pt) 2001-05-31
KR100683374B1 (ko) 2007-02-15
ES2235770T3 (es) 2005-07-16
DK1108787T3 (da) 2005-04-04
EP1108787A3 (en) 2001-08-29

Similar Documents

Publication Publication Date Title
BRPI0015846B8 (xx)
KR100968141B1 (ko) 세포 배양물에서 바이러스의 증식 방법
DK0904351T3 (da) Dyreceller og fremgangsmåder til replikationen af influenzavirus
FR08C0046I2 (fr) Reconstitution in vitro de virus a arn de polarite negative segmentes
DE69535940D1 (de) Verfahren zur Herstellung von biologischen Produkten in Protein-freiem Kultur
KR20120033334A (ko) 백신 제조를 위한 고역가 폴리오바이러스의 제조
JP2010138205A (ja) Ｍｄｃｋ細胞懸濁培養物において薬物または診断剤の活性成分を生成する方法
ATE231729T1 (de) Verfahren zur industriellen herstellung eines japanischen enkephalitis impfstoffes, und so erhaltener impfstoff
MXPA05009096A (es) Metodo de cultivo celular libre de animal.
DE69327623D1 (de) Herstellungsmethode um multiple-sklerose-virus-assoziierte infizierte zellen zu erhalten
ES8104405A1 (es) Procedimiento para preparar una vacuna de virus de gripe
US3935066A (en) Cell lines
JPH0998778A (ja) マレク病ワクチン
KR102696955B1 (ko) 무혈청 배지에서 부유배양이 가능한 신규한 Vero 세포주, 이의 제조 방법 및 상기 신규 세포주를 이용한 백신용 바이러스 제조 방법
ATE486124T1 (de) Keratinozyten-kulturverfahren und verwendung davon
Igarashi A mutant of Chikungunya virus isolated from a line of Singh's Aedes albopictus cells by plaque formation on virus-sensitive cloned cells obtained from another Singh's A. albopictus cell line
Rafajko Routine establishment of serial lines of hamster embryo cells transformed by adenovirus type 12
CA1064395A (en) Cell strain and virus culture
RU93048664A (ru) Способ суспензионного культивирования филовирусов в клеточных культурах на микроносителях
JP2016202147A (ja) 繊維材質支持体を用いたウイルス培養法
NL7709998A (en) Foetal canine lung diploid cell line - for virus cultures esp. for rabies vaccine prodn.
BG61384B1 (bg) метод за получаване на жива атенуирана клетъчно-културална ваксина против псевдочума по птиците